DPYSL3B is a regulator of chemoresistance via DNA repair and metabolic reprogramming in prostate cancer
Roosa Kaarijärvi, Heidi Kaljunen, Nella Itkonen, Kseniia Bureiko, Kirsi Ketola
This study identifies DPYSL3B as a regulator of chemoresistance in prostate cancer by enhancing DNA repair and metabolic reprogramming, with implications for therapeutic targeting.
bioRxiv · Jul 3, 2025 · PreprintCancer Biology